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Plasmodium knowlesi causes severe and fatal malaria in Malaysia. Microscopic misdiagnosis is common and may delay appro-
priate treatment. P. knowlesi can cross-react with “species-specific” parasite lactate dehydrogenase (pLDH) monoclonal anti-
bodies used in rapid diagnostic tests (RDTs) to detect P. falciparum and P. vivax. At one tertiary-care hospital and two district
hospitals in Sabah, we prospectively evaluated two combination RDTs for malaria diagnosis by using both a pan-Plasmodium-
pLDH (pan-pLDH)/P. falciparum-specific-pLDH (Pf-pLDH) RDT (OptiMAL-IT) and a non-P. falciparum VOM-pLDH/Pf-
HRP2 RDT (CareStart). Differential cross-reactivity among these combinations was hypothesized to differentiate P. knowlesi
from other Plasmodium monoinfections. Among 323 patients with PCR-confirmed P. knowlesi (n 193), P. falciparum (n
93), and P. vivax (n 37) monoinfections, the VOM-pLDH individual component had the highest sensitivity for nonsevere
(35%; 95% confidence interval [CI], 27 to 43%) and severe (92%; CI, 81 to 100%) P. knowlesi malaria. CareStart demonstrated a
P. knowlesi sensitivity of 42% (CI, 34 to 49%) and specificity of 74% (CI, 65 to 82%), a P. vivax sensitivity of 83% (CI, 66 to 93%)
and specificity of 71% (CI, 65 to 76%), and a P. falciparum sensitivity of 97% (CI, 90 to 99%) and specificity of 99% (CI, 97 to
100%). OptiMAL-IT demonstrated a P. knowlesi sensitivity of 32% (CI, 25 to 39%) and specificity of 21% (CI, 15 to 29%), a P.
vivax sensitivity of 60% (CI, 42 to 75%) and specificity of 97% (CI, 94 to 99%), and a P. falciparum sensitivity of 82% (CI, 72 to
89%) and specificity of 39% (CI, 33 to 46%). The combination of CareStart plus OptiMAL-IT for P. knowlesi using predefined
criteria gave a sensitivity of 25% (CI, 19 to 32%) and specificity of 97% (CI, 92 to 99%). Combining two RDT combinations was
highly specific for P. knowlesi malaria diagnosis; however, sensitivity was poor. The specificity of pLDH RDTs was decreased for
P. vivax and P. falciparum because of P. knowlesi cross-reactivity and cautions against their use alone in areas where P. knowlesi
malaria is endemic. Sensitive P. knowlesi-specific RDTs and/or alternative molecular diagnostic tools are needed in areas where
P. knowlesi malaria is endemic.
Human malaria due to the simian parasite Plasmodiumknowlesi has now been reported in all countries throughout
Southeast Asia except Laos and East Timor (1–9). In Malaysian
Borneo, P. knowlesi is the most common cause of human malaria
(10, 11) and commonly causes severe disease, with fatal cases also
reported (12–16). Early diagnosis of P. knowlesi infection is im-
portant; with its 24-h life cycle, it can rapidly cause high para-
sitemia and is three times as likely as P. falciparum to cause severe
malaria (15). Microscopy remains the gold standard for malaria
diagnosis across Asia. However, microscopic diagnosis of P.
knowlesi remains problematic, since the species is nearly indistin-
guishable from P. malariae (17) and is frequently confused with P.
falciparum and P. vivax (18). Misdiagnosis of P. knowlesi has im-
portant clinical implications, including inappropriate treatment
in regions without unified treatment strategies, failure to admin-
ister antihypnozoite treatment for P. vivax malaria (18), and fail-
ure to recognize patients at risk of severe disease (16). Public
health surveillance of P. knowlesi is also compromised by inaccu-
rate microscopic reporting.
Malaria rapid diagnostic tests (RDTs) using immunochro-
matographic capture techniques provide an alternative method of
diagnosis and have been increasingly deployed in areas where ma-
laria is endemic. The tests can be conducted by staff with minimal
training, and results are rapidly available. In the most recent WHO
round 4 malaria RDT product testing results, composite test pos-
itivity had considerably increased, with the best-performing tests
for P. falciparum and P. vivax approaching 100% even at a parasite
count of 200/l (19). These RDTs utilize monoclonal antibodies
targeting specific antigens such as P. falciparum histidine-rich
protein 2 (Pf-HRP2) or Plasmodium genus- or species-specific
parasite lactate dehydrogenase (pLDH). Although no P. knowlesi-
specific monoclonal antibody has been developed, P. knowlesi has
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been shown to cross-react with P. falciparum- and P. vivax-“spe-
cific” pLDH (20).
Several case reports of returned travelers with PCR-confirmed
P. knowlesi monoinfection have demonstrated this cross-reactiv-
ity, with Plasmodium genus pLDH-, P. falciparum pLDH-, and P.
vivax pLDH-based RDTs all yielding positive results but with poor
sensitivity at low parasite counts (21–24). In a previous prospec-
tive evaluation of RDTs for P. knowlesi malaria, a pan-pLDH-
based RDT demonstrated a moderate overall sensitivity for P.
knowlesi of 74% (95/129; 95% confidence interval [CI], 65 to
80%), which improved for pretreatment samples (88%; 30/34; CI,
73 to 95%) and for severe disease (95%; 36/38; CI, 83 to 99%) (25).
Neither this test nor a more poorly performing aldolase-based
RDT also evaluated in that study approached a sensitivity of 100%
for parasitemias of100/l, which was previously defined as nec-
essary for use as a clinically sufficient malaria diagnostic tool (26,
27). Moreover, neither RDT was able to distinguish P. knowlesi
from P. vivax.
As P. knowlesi cross-reacts with a proportion of monoclonal
antibodies targeting both P. falciparum and P. vivax pLDHs but
does not cross-react with Pf-HRP2, we and others (20) have
hypothesized that a combination of RDTs containing these test
components may be used for differentiating P. knowlesi, P. falcip-
arum, and P. vivax malaria infections (Table 1). Current commer-
cial RDTs do not routinely specify the exact epitopes present on
the monoclonal antibodies used to target Plasmodium species
pLDHs and whether they are shared (20), meaning that it is not
possible to ascertain the potential P. knowlesi-binding capacity of
previously untested pLDH-based RDTs. We therefore prospec-
tively evaluated the sensitivity and specificity of a combination of
two RDTs for the diagnosis of P. knowlesi malaria.
MATERIALS AND METHODS
Study sites and referral system. This study was conducted at three hos-
pitals in Sabah, Malaysian Borneo: Kudat District Hospital (KDH), Kota
Marudu District Hospital (KMH); and Queen Elizabeth Hospital (QEH),
the corresponding adult tertiary-care referral center in the state capital
Kota Kinabalu. QEH services a catchment area along the northwestern
coast of Sabah with a population of 1.14 million people in six districts.
Malaria patients from this area are either admitted to their primary dis-
trict hospital or referred to QEH with an accompanying pretreatment
blood film and whole-blood sample if they meet state transfer guidelines.
These include a thick blood film reported as 4 (indicating10 parasites/
high-power microscopy field) or any evidence of severe malaria, with
treatment prior to transfer. Malaria patients from the local Kota Kinabalu
area are admitted directly to QEH.
Subjects. All of the patients presenting to QEH from September 2011
to July 2013 or to KDH and KMH from October 2012 until July 2013 with
a microscopic diagnosis of malaria were eligible for inclusion in this study.
This included 14 adults with severe (n 3) or nonsevere (n 11) malaria
previously reported (15, 18). District sites were included to allow pretreat-
ment evaluation of children 1 year of age and adults in a primary-care
setting where, in contrast to a tertiary-care referral hospital, malaria cases
are more often nonsevere and have lower parasite counts (12, 28). All of
the participants were nonpregnant with no major comorbidities and
had not previously been enrolled in this study. On the basis of PCR
testing, patients who were negative (n 19), did not have a result (n
6), or had mixed infections with Plasmodium species (n  3) were ret-
rospectively excluded. Malaria severity was defined by modified 2010
WHO criteria (15, 29). Written informed consent was provided by pa-
tients or their relatives. Approvals were obtained from the Ethics Com-
mittees of the Malaysian Ministry of Health and the Menzies School of
Health Research.
RDT selection. On the basis of the WHO round 1 and 2 malaria RDT
product test results available at the time of study design (30) (Table 2),
RDTs were chosen according to the combined potential specificity of the
individual test components for P. knowlesi malaria (Table 1). The test
components with the highest reported sensitivities for P. falciparum-spe-
cific and non-P. falciparum pLDHs were selected. They were OptiMAL-IT
(DiaMed AG), which detects P. falciparum-specific and pan-Plasmodium
sp. pLDHs, and CareStart Malaria (Pf/VOM) Combo (Access Bio Inc.),
which detects the Pf-HRP2 antigen and non-P. falciparum pan-pLDH.
Despite potential positive cross-reactivity with Pf-LDH, it may be pos-
sible to differentiate a P. knowlesi monoinfection from a P. falciparum
monoinfection by using its lack of reactivity with the Pf-HRP2 compo-
nent. It may be possible to differentiate a P. knowlesi monoinfection
from a P. vivax monoinfection by using the lack of reactivity of the latter
with Pf-LDH. While this RDT combination will not distinguish a P.
knowlesi monoinfection from a mixed P. knowlesi-P. vivax infection, the
latter appears rare in Malaysian Borneo, accounting for 5/387 (1.3%) (15)
and 1/188 (0.5%) (14) PCR-confirmed malaria cases in two recent studies.
Study procedures. Demographic and clinical information was re-
corded on standardized case record forms. Pretreatment venous blood
TABLE 1 Predefined clinical specificity reference for RDT component
combinations
Parasite
Combined specificityd of:
CareStart OptiMAL-IT
VOM-pLDH Pf-HRP2 Pan-pLDH Pf-pLDH
P. knowlesia,b    
P. falciparumc    
P. vivax    
P. malariae    
P. knowlesi-P. vivax    
P. knowlesi-P. falciparum    
P. falciparum-P. vivax    
a P. knowlesi monoinfection or mixed P. knowlesi-P. vivax infection cannot be
differentiated.
b VOM-pLDH and pan-pLDH are not required to differentiate P. knowlesi from P.
falciparum or P. vivax monoinfection.
c Pf-HRP2 is highly specific for P. falciparum; therefore, a positive Pf-HRP2 result
indicates P. falciparum infection regardless of the OptiMAL-IT result.
d Symbols:, specific;, not specific;, equivocal.
TABLE 2 Test positivity in WHO RDT product testing rounds 1 and 2a
Test
% Test positivity with:
200 parasites/l 2,000 or 5,000 parasites/l
P. falciparum P. vivax P. falciparum P. vivax
Pf-HRP2/VOM-pLDH (CareStart) 89 80 100 100
Pf-pLDH/pan-pLDH (OptiMAL-IT) 37 95 96 100
a Data are from reference 30.
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was collected in a labeled EDTA or citrate-theophylline-adenosine-dipyr-
idamole tube. RDTs were transported directly to the study sites by regis-
tered courier from the manufacturer in the United States (CareStart) and
through a local distributer (OptiMAL-IT). RDTs were subsequently
stored out of direct sunlight in monitored, air-conditioned research lab-
oratories at 22°C. Batch numbers and expiration dates were documented.
RDTs were taken to the patient enrollment area, where the temperature
and humidity did not exceed 32°C and 74%, respectively. All of the RDTs
were packaged and sealed individually with desiccant and used immedi-
ately after opening, in accordance with the manufacturers’ instructions.
Results were recorded by one of two research laboratory technicians
blinded to the microscopy diagnosis, with regular cross-checking by the
study clinician to ensure consistent reporting. Interobserver agreement
was tested at the district sites, with a research staff member reading the test
first, followed 5 min later by a second person blinded to the initial reading.
In the event of discordant results, a third person also blinded read the test,
with the final result being the most common reading. Results were re-
corded as follows: negative, no clearly visible line; 1, faint line; 2, line
darker than 1 but lighter than the control; 3, same as the control line; 4,
line darker than the control. Thick and thin blood films were prepared on
enrollment and examined by microscopists at referring district hospitals
or at QEH, with slides later cross-checked by an experienced research
microscopist. Parasite density was quantified by the research microscopist
using pretreatment slides and reported as the number of parasites per 200
leukocytes or per 1,000 erythrocytes and converted to the number of par-
asites per microliter by using the patient’s leukocyte count or hematocrit,
respectively. Where pretreatment slides were unavailable (13/327 [4%]),
referring hospital microscopy was used and the grades 1 to 4 were
converted into numbers of parasites per microliter by using the relevant
median parasite density. Parasite DNA was extracted, and PCR was per-
formed as previously described for P. falciparum, P. vivax, P. ovale, and P.
malariae (31) or P. knowlesi (32) detection.
Statistical analysis. Data were analyzed by using STATA, version 12
(StataCorp LP, College Station, TX). Intergroup differences were com-
pared by using the Kruskal-Wallis test for nonnormally distributed con-
tinuous variables and a 2 test for categorical variables. The variables
measured included the numbers of true positives, true negatives, false
positives, and false negatives. PCR results were used as the gold standard,
with Plasmodium species monoinfections compared against all of the
other PCR-positive Plasmodium species. Test sensitivity was defined as
true positives/(true positives  false negatives), and test specificity was
defined as true negatives/(true negatives  false positives). Ninety-five-
percent confidence intervals (CIs) were estimated by Wilson’s method.
Logistic regression was used to assess the relationship between sensitivity
and parasite count and also the usefulness of RDT band intensity as a
predictor of severity. Interobserver agreement between the first and sec-
ond readings was measured by using the kappa coefficient. Spearman’s
correlation coefficient was used to assess the association between RDT
band intensity and the parasite count.
RESULTS
Baseline demographic and clinical features. From October 2012
until July 2013, RDTs were conducted for 193, 93, 37, and 3 pa-
tients with PCR-confirmed P. knowlesi, P. falciparum, P. vivax,
and P. malariae monoinfections, respectively. This included 321
patients (P. knowlesi, n 189; P. falciparum, n 92; P. vivax, n
37; P. malariae, n 3) tested with the pan-pLDH/Pf-pLDH (Op-
tiMAL-IT) test. The VOM-pLDH/Pf-HRP2 (CareStart) test was
performed for 301 patients (P. knowlesi, n  178; P. falciparum,
n  85; P. vivax, n  35; P. malariae, n  3). Their baseline
demographics are shown in Table 3. Patients with P. knowlesi ma-
laria were older than those with P. falciparum or P. vivax malaria
(median ages, 40, 30, and 27 years, respectively; P 	 0.001) and
more likely to be male (81, 73, and 68%, respectively; P 0.031).
The majority of the malaria patients were enrolled at the QEH
tertiary-care study site for all of the Plasmodium species. P.
knowlesi patients enrolled at district hospitals were younger (me-
dian age, 33 versus 44 years; P  0.001), were less likely to have
severe malaria (5 versus 22%; P 0.001), and had lower median
parasite counts (1,436 versus 3,802/l; P 0.001) than those en-
rolled at the tertiary-care hospital. For nonsevere malaria, P.
knowlesi malaria patients had a lower median parasite count
(1,701/l) than P. falciparum malaria patients (P 0.033) but not
P. vivax malaria patients (P 0.918).
Microscopy. Among 193 patients with PCR-confirmed P.
knowlesi infection, only 33 (17%) were accurately reported as P.
knowlesi or “P. malariae/?P. knowlesi” by hospital microscopists,
while 109 (56%) were reported as P. malariae (morphologically
indistinguishable from P. knowlesi and the default reporting no-
menclature from previous state guidelines). Considered as a single
group, this gave a sensitivity of 74% (CI, 67 to 80%) and a speci-
ficity of 89% (CI, 82 to 94%) for P. knowlesi. Our dedicated re-
search microscopist correctly identified 158 of 193 P. knowlesi
blood films (sensitivity, 83% [CI, 76 to 88%]; specificity, 93% [CI,
87 to 96%]).
RDT sensitivity. The VOM-pLDH test component had the
highest sensitivity (77/178; 43%; CI, 36 to 51%) for P. knowlesi
malaria overall but still performed poorly (Table 4). For P. vivax,
despite a median parasite count of 3,366/l, the VOM-pLDH test
performance (29/35; 83% sensitivity; CI, 70 to 96%) was more in
line with the reported WHO composite test positivity of 80% at
200 parasites/l than the reported 100% with 2,000 to 5,000 par-
asites/l (30). For P. falciparum, three false-positive VOM-pLDH
results were recorded, with parasite counts ranging from 9,079 to
21,972/l. For the PCR-confirmed P. malariae cases, VOM-
pLDH demonstrated test positivity (2/3; 67%; CI, 9 to 99%); how-
ever, the small numbers did not allow meaningful evaluation. The
pan-pLDH test component was insufficiently sensitive for all of
the species, with sensitivities of 30% (CI, 24 to 37%), 68% (CI, 52
to 83%), 78% (CI, 70 to 87%), and 67% (CI, 0 to 100%) for P.
knowlesi, P. vivax, P. falciparum, and P. malariae, respectively. The
Pf-pLDH test also demonstrated poor sensitivity for P. knowlesi
(55/190; 29%; CI, 22 to 35%) and suboptimal stand-alone perfor-
mance for P. falciparum (74/92; 80%; CI, 72 to 89%), despite a
median P. falciparum parasitemia of 5,832/l. The overall sensi-
tivity of the OptiMAL-IT RDT (i.e., a positive Pf-pLDH and/or
pan-pLDH test result) for the detection of P. knowlesi (32% [CI,
25 to 39%]) was only a marginal improvement on the individual
test components. The CareStart overall sensitivity for P. knowlesi
of 42% (CI, 34 to 49%) was slightly less than the VOM-pLDH
standalone sensitivity of 43% because of four false-positive Pf-
HRP2 results. The sensitivities of the VOM-pLDH, pan-pLDH,
and Pf-pLDH tests for P. knowlesi malaria were all lower at the
district sites than at the tertiary-care site (35 versus 49% [P 
0.061], 13 versus 42% [P 	 0.0001], and 13 versus 40% [P 	
0.001], respectively).
Sensitivity and parasitemia. Increasing P. knowlesi para-
sitemia correlated with test sensitivity for VOM-pLDH (P 	
0.001), pan-pLDH (P 0.001), andPf-pLDH (P 0.004) (Fig. 1A
and B). Thirty-one percent of the P. knowlesi patients had a para-
site count of	1,000/l, and in this group only 12% had a positive
VOM-pLDH test. Among the 27% of P. knowlesi patients with a
parasite count of10,000/l, 81% (39/48) had a positive VOM-
pLDH test result, which increased to 100% (13/13) for those with
RDTs for Diagnosis of P. knowlesi Malaria
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a parasite count of100,000/l. Despite the lowest recorded par-
asite count for a positive VOM-pLDH test result being 50/l, the
median positive result was 7,089/l and the highest negative result
was 40,807/l. For both pan-pLDH and Pf-pLDH, the lowest P.
knowlesi parasitemia detected was 26/l and the highest was
641,464/l. The highest negative result for P. knowlesi with both
pan-pLDH and Pf-pLDH was 425,784/l. The relationship be-
tween test positivity and parasitemia was also apparent for P. fal-
ciparum with the pan-pLDH (P  0.048) and Pf-pLDH (P 
0.045) tests. In contrast, P. vivax had a smaller range of parasite
counts (76 to 60,288/l) and no statistically significant relation-
ship between parasitemia and the sensitivity of any of the different
test components.
Sensitivity and clinical severity. The VOM-pLDH test had a
higher sensitivity among severe P. knowlesi malaria patients (24/
26; 92%; CI, 81 to 100%) than the pan-pLDH (20/28; 71%; CI, 54
to 89%; P 0.049) and Pf-pLDH (17/28; 61%; CI, 41 to 80%; P
0.006) test components. For P. vivax, both the VOM-pLDH and
pan-pLDH tests of all three severe-malaria patients were positive.
All of the severe P. falciparum malaria patients tested with Pf-
HRP2 were positive (14/14; 100%); however, only 14/16 (86%; CI,
69 to 100%) and 13/16 (81%; CI, 60 to 100%) had positive Pf-
LDH and pan-pLDH test results, respectively.
Line intensity. The intensity of the test line was strongly asso-
ciated with an increasing parasite count for P. knowlesi malaria
with all of the test components, with Spearman correlation coef-
ficients of 0.616 (P 	 0.001), 0.408 (P 	 0.001), and 0.376 (P 	
0.001) for VOM-pLDH, pan-pLDH, and Pf-pLDH, respectively
(Fig. 2). For positive VOM-pLDH tests, the highest line intensity
reading of 4 did not independently predict severe P. knowlesi
malaria (P 0.595).
Interobserver agreement. Both pan-pLDH/Pf-LDH (n 95)
and VOM-pLDH/Pf-HRP2 (n  89) demonstrated excellent in-
terobserver agreement, with kappa values of 0.9 for all of the
TABLE 3 Baseline demographics, clinical severity, and parasitemia of enrolled subjects
Species (no. of patients)
or parameter
No. (%) of patients Median age, yr (IQRa) [range] No. (%) of males
Tertiary-care
Hospital
District
hospital Total
Tertiary-care
hospital District hospital Total
Tertiary-care
hospital
District
hospital
P. knowlesi (193) 114 (59) 79 (41) 40 (26–51) [3–94] 44 (30–52) [16–81] 33 (20–48) [3–72] 157 (81) 97 (85) 60 (75)
P. falciparum (93) 91 (98) 2 (2) 30 (21–44) [13–75] 30 (21–44) [13–75] 43 (15–71) [15–71] 68 (73) 68 (75) 0
P. vivax (37) 23 (62) 14 (38) 27 (11–39) [1–62] 31 (27–42) [15–62] 11 (4–12) [1–39] 25 (68) 18 (78) 7 (50)
P. malariae (3) 1 (33) 2 (66) 21 (13–25) [13–25] 25 17 (13–21) [13–21] 1 (33)
P value for:
P. knowlesi vs
P. falciparum
0.006 	0.001 0.52 0.133 0.064 0.019
P. knowlesi vs P. vivax 	0.001 0.023 	0.001 0.069 0.418 0.058
a IQR, interquartile range.
TABLE 4 Sensitivity and specificity of RDTs and their components for each Plasmodium species
Test and parameter
Proportion, % (CI)
P valueP. knowlesi P. vivax P. falciparum P. malariae
CareStart
VOM-pLDH, sensitivity 77/178, 43 (36–51) 29/35, 83 (70–96) 3/85, 4 (0–8)d 2/3, 67 (0–100) 	0.0001a
Pf-HRP2, sensitivity 4/183, 2 (0–4)d 1/35, 3 (0–9)d 86/87, 99 (97–100) 0/3, 0
OptiMAL-IT
Pan-pLDH, sensitivity 57/189, 30 (24–37) 25/37, 68 (52–83) 72/92, 78 (70–87) 2/3, 67 (0–100) 	0.0001b
Pf-pLDH, sensitivity 55/190, 29 (22–35) 5/37, 14 (2–25)d 74/92, 80 (72–89) 0/3, 0 	0.0001c
CareStart (VOM-pLDH Pf-HRP2)
Sensitivity 74/178, 42 (34–49) 29/35, 83 (66–93) 82/85, 97 (90–99) 2/3, 67 (9–99)
Specificity 91/123, 74 (65–82) 189/266, 71 (65–76) 214/216, 99 (97–100) 194/298, 35 (30–41)
OptiMAL-IT (pan-pLDH Pf-pLDH)
Sensitivity 61/191, 32 (25–39) 22/37, 60 (42–75) 75/92, 82 (72–89) 2/3, 67 (9–99)
Specificity 28/132, 21 (15–29) 276/285, 97 (94–99) 141/231, 39 (33–46) 290/319, 91 (87–94)
a P. knowlesi compared against P. vivax only.
b P. knowlesi compared against other Plasmodium species.
c P. knowlesi compared against P. falciparum only.
d False positives.
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tests. No tests were repeated at the district hospital sites; however,
this was not documented at the tertiary-care site.
Combined test specificity and sensitivity. Individual test
component specificity for P. knowlesi is not clinically useful, as the
individual test components cannot differentiate P. knowlesi from
other Plasmodium species. However, a combination of the tests
could theoretically distinguish a P. knowlesimonoinfection from a
P. vivax, P. falciparum, or P. malariae monoinfection (Table 1).
The use of this predefined RDT combination to diagnose PCR-
confirmed P. knowlesi-infected patients yielded 45/181 positive
results, with a sensitivity for P. knowlesi diagnosis lower than that
of hospital microscopy (25% [CI, 19 to 32%] versus 74% [CI, 67
to 80%]; P	 0.001) but a higher specificity (96% [CI, 91 to 99%]
versus 89% [CI, 82 to 94%]; P 0.030) (Table 5). The sensitivity
of the RDT combination forP. knowlesidiagnosis was also lower at
the district hospitals (10% [CI, 5 to 19%]) than at the tertiary-care
hospital (36% [CI, 26 to 46%]; P	 0.001).
DISCUSSION
P. knowlesi cross-reactivity was demonstrated with all of the
pLDH-based test components evaluated in this study; however,
the sensitivities of each test component and of the RDTs overall
(32 and 42% for OptiMAL-IT and CareStart, respectively) were
insufficient for the diagnosis of P. knowlesi malaria. Binding affin-
ity appeared to be strongly related to parasitemia, with test sensi-
tivity particularly poor at lower parasite counts. P. knowlesi pa-
tients, including both adults and children, with nonsevere malaria
have lower parasitemias than those with nonsevere P. falciparum
malaria, with P. knowlesi parasitemias particularly low at the dis-
trict level. The lack of test sensitivity for these patients is high-
lighted by the finding that the median parasitemia detected by the
VOM-pLDH test (7,089 parasites/l) far exceeds the median par-
asitemia among nonsevere P. knowlesi patients presenting to a
district hospital (1,040 parasites/l) or a tertiary-care hospital
(2,133 parasites/l). Although the VOM-pLDH test was positive
among all of the patients with P. knowlesi parasite counts of
100,000/l and among 92% of the patients with severe P.
knowlesi malaria, false-negative results occurred among patients
with parasite counts of up to 40,807/l. Given that the risk of
severe disease with P. knowlesi is 11-fold higher with a parasitemia
of 20,000/l (15), false-negative VOM-pLDH test results with
parasite counts above this level are clearly unsatisfactory.
The insufficient sensitivity of each of the RDTs evaluated in the
present study for P. knowlesi diagnosis is consistent with the lack
of sensitivity demonstrated in other recent series evaluating RDT
performance in hospital settings in countries where P. knowlesi
malaria is endemic. These include tests incorporating the follow-
TABLE 3 (Continued)
No. (%) of patients with severe
malaria Median no. of parasites/l (IQRa) [range]
Total
Tertiary-care
hospital
District
hospital All patients Nonsevere malaria Severe malaria
Tertiary-care
hospital District hospital
29 (15) 25 (22) 4 (5) 2301 (672–641464)
[30–641464]
1701 (493–7573)
[30–90683]
56784 (5300–144968)
[979–641464]
3802 (1152–18442)
[88–641464]
1436 (320–7515)
[30–143184]
16 (17) 16 (100) 0 5832 (1464–19000)
[26–606108]
4386 (1464–17208)
[26–247897]
17912 (6554–106070)
[33–606108]
6254 (1464–21972)
[26–606108]
570 (33–1107)
[33–1107]
3 (8) 3 (100) 0 3366 (371–13593)
[76–60288]
3004 (371–12544)
[76–60288]
4453 (4025–19520)
[4025–19520]
3381 (1332–6581)
[210–19520]
3004 (600–12544)
[76–60288]
0 675 (77–1212)
[77–1212]
675 (77–1212)
[77–1212]
1212 (1212–1212)
[1212–1212]
376 (77–675)
[77–675]
0.623 0.329 0.009 0.033 0.009 0.308 0.388
0.271 0.337 0.395 0.918 0.483 0.165 0.342 0.417
FIG 1 (A) Sensitivity of the VOM-pLDH component of the CareStart RDT by parasite count for P knowlesi and P. vivax infections. Vertical lines represent CIs.
(B) Sensitivity of the pan-pLDH component of the OptiMAL-IT RDT by parasite count for P knowlesi, P. vivax, and P. falciparum infections. Vertical lines
represent CIs.
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ing antibody components: pan-pLDH (First-Response, 74% sen-
sitivity) (25),Pf-pLDH/pan-pLDH (OptiMAL-IT, 71% sensitivity
with fresh isolates) (33), Pv-pLDH/pan-pLDH (Paramax-3, 40%
sensitivity with fresh isolates) (33), and pan-Plasmodium aldolase
(ParaHit, 23% sensitivity with fresh isolates [25]; BinaxNOW,
29% sensitivity with fresh isolates [33]).
The cross-reactivity of P. knowlesi in RDTs utilizing “species-
specific” P. falciparum or P. vivax pLDH monoclonal antibodies
means that their specificity for these other species is affected. This
has important implications for the use of RDTs to diagnose P.
falciparum and P. vivax infections in areas of Southeast Asia where
P. knowlesi is also prevalent. We demonstrate here that the previ-
ously reported specificities of the OptiMAL-IT RDT elsewhere in
Southeast Asia of 94.7% for P. falciparum (with or without other
species) and 96.5% for non-P. falciparum species (34) are not
applicable to areas with higher P. knowlesi endemicity. The Opti-
MAL-IT RDT, in particular, had a much lower specificity for P.
falciparum of 39%. The CareStart RDT specificity of 71% for
P. vivax was also lower than would be expected in areas where P.
knowlesi is not endemic.
A limitation of the RDTs used in this study was that even when
they were used in combination they could not differentiate be-
tween P. knowlesi and mixed P. knowlesi-P. vivax infections, which
would have implications for radical P. vivax cure. In Malaysian
Borneo, the prevalence of mixed P. knowlesi-P. vivax infections
appears to be low, with only one reported PCR-confirmed case in
Sarawak (14) and 5/387 (1.3%) in our recent prospective study in
Sabah (15). A separate study in Sabah reported 83 P. knowlesi-P.
vivax mixed infections (35) but used earlier PCR primers that can
include a false-positive P. vivax result for true P. knowlesi monoin-
fections (32). In other areas where P. knowlesi malaria is endemic,
such as Thailand, India, and Myanmar, mixed P. knowlesi-P. vivax
infections have been reported, with prevalences ranging from	1
to 9% (3, 36, 37). Comparing specificity against controls without
malaria may also have assisted in ascertaining whether false-pos-
itive results may have been interpretation or reporting errors
rather than real cross-reactivity between pLDH monoclonal anti-
bodies directed at other Plasmodium species. While it is recom-
mended that RDT evaluations be conducted against the gold stan-
dard, microscopy (38), the known difficulties in microscopic
diagnosis and reporting of P. knowlesi (18) meant that the RDT
sensitivities were analyzed by using PCR results.
We hypothesized that the use of a combination of pLDH and
HRP2 tests may make it possible to differentiate P. knowlesi from
other Plasmodium monoinfections. While the RDT combination
did give a high specificity of 96% for P. knowlesi against other
Plasmodium monoinfections, the low overall sensitivities prevent
these RDTs from replacing standard microscopy as a diagnostic
tool for P. knowlesi in this region. The cost of using two commer-
cial RDTs following positive microscopy to improve specificity is
also not feasible in many settings. For P. falciparum, RDTs con-
taining an HRP2 component that does not cross-react with P.
knowlesi should therefore be used. The ideal RDT combination
would also contain aP. vivax-specific pLDH monoclonal antibody
that does not cross-react with P. knowlesi and would therefore
enable accurate diagnosis of P. vivax in order to guide the need for
radical primaquine therapy. Other, more sensitive, molecular di-
agnostic tools, such as loop-mediated isothermal PCR (LAMP)
targeting the AMA-1 or beta-tubulin P. knowlesi gene, have dem-
onstrated test detection limits as low as 10 to 102 copies, respec-
tively, with reported sensitivities and specificities of 100% (39, 40).
The sensitivity of LAMP may be ideal at a district hospital level in
Malaysia, given that the majority of P. knowlesi patients present
with very low parasite counts. LAMP is also at least as sensitive and
specific as nested PCR (40), with the added advantage of being
able to be conducted with less training and equipment and at
isothermal temperatures. However, the benefit of improving the
sensitivity of immunochromatographic RDTs for use in more re-
mote clinics with declining rates of malaria infection due to other
Plasmodium species and parallel deskilling of health clinic level
microscopists should encourage the development of P. knowlesi-
FIG 2 Parasite counts by VOM-pLDH line intensity for P knowlesi and P.
vivax infections. Horizontal lines indicate medians, boxes indicate interquar-
tile ranges, and vertical lines indicate ranges.
TABLE 5 Performance characteristics of combined use of CareStart and OptiMAL-IT RDTs compared with those of microscopy for the diagnosis of
P. knowlesi malaria
Method and result
No. of patients with:
% Sensitivity (CI) % Specificity (CI) % PPVb (CI) % NPVc (CI)
Likelihood ratio
PCR-confirmed
P. knowlesi
PCR-confirmed other
Plasmodium species
Positive
test
Negative
test
RDTsa
Positive 45 5 25 (19–32) 96 (91–99) 90 (78–97) 47 (40–53) 6.17 0.78
Negative 136 119
Microscopy
Positive 143 15 74 (67–80) 89 (82–94) 91 (85–95) 70 (63–77) 6.57 0.29
Negative 50 118
a Equivocal result for VOM-pLDH, negative result for Pf-HRP2, equivocal result for pan-pLDH, and positive result for Pf-pLDH.
b PPV, positive predictive value.
c NPV, negative predictive value.
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specific monoclonal antibodies. Improved diagnosis ofP. knowlesi
would assist in the collection of prevalence data to guide public
health strategies for this emerging and potentially fatal infection.
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